Novogen Appoints Three New Directors
20 sept. 2010 08h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) - Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors.
Of the three...
Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
18 juin 2010 09h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
17 juin 2010 09h00 HE
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
01 juin 2010 08h31 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards Appoints New President and CEO
26 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Novogen Announces New Executive Service Agreements
31 mars 2010 08h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - March 31, 2010) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) advises that it has entered into new executive service agreements with its seven most senior executives.
...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
31 mars 2010 08h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
08 févr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5,...
Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
20 avr. 2009 08h00 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented
yesterday at the Annual Meeting of the American Association for Cancer
Research in Denver has demonstrated that...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
14 avr. 2009 08h20 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...